Intravenous (IV) Iron Drugs - 2015 Global Strategic Business Report - A Glimpse of Regulations in the US and Europe

News provided by

Mar 13, 2015, 07:17 ET

DUBLIN, Mar. 13, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/qn3kz9/intravenous_iv) has announced the addition of the "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 17 companies including many key and niche players such as:

Actavis, Inc. (US)
AMAG Pharmaceuticals, Inc. (US)
Fresenius Medical Care AG & Co. KGaA (Germany)
Galenica Ltd. (Switzerland)
Vifor Pharma Ltd. (Switzerland)
Luitpold Pharmaceuticals, Inc. (US)
American Regent, Inc. (US)
Pharmacosmos A/S (Denmark)
Sanofi US (US)
Takeda Pharmaceutical Company Limited (Japan)

Key Topics Covered:

1. OUTLOOK

IV Iron Drugs Market
A Quick Primer
US and Europe Dominate IV Iron Market
Asia-Pacific
The Fastest Growing Market
Recession Fails to Affect Market Growth
Positive Outlook for the Healthcare Industry Signals Prospects

2. INDUSTRY OVERVIEW & TRENDS

IDA and Treatment
An Overview
Dialysis Clinics
Major Market for IV Iron Supplements
IV Iron Drugs
An Overview
Select IV Iron Drugs Prescribed for Iron Deficiency
Galenica
The Global Leader in IV Iron
Venofer®
Galenica's Wonder Drug
Venofer Continues to Lose Ground
Ferinject/Injectafer
A Promising Revenue Spinner for Galenica
Feraheme Surges Ahead; Manufacturer Eyes Expansion of Indications
The Vulnerable Ageing Population Supports Demand
Changing Preferences Favor IV Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
Chronic Kidney Disease
The Predominant Growth Factor
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
Anemia in Heart Failure
A Market with Huge Potential
Chemotherapy Induced Anemia to Promote IV Iron Supplements
Correction of IDA in Pregnancy Signals Opportunities
Women's Health
Key Growth Opportunity
Perioperative and Postoperative Anemia
A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Peginesatide
A Possible Threat to IV Iron
Dosing Limitations Plague IV Iron Market
Select Therapeutic Areas and the Required Iron Doses

3. REGULATORY OVERVIEW

Increasing Trend towards Bundled Reimbursements
A Glimpse of Regulations in the US and Europe
Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs
Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada

4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS

Iron
A Vital Element
Iron-Deficiency Anemia
Intravenous Therapy
Patients of Chronic Illnesses, the Elderly and Women
The High Risk Population
Treatment for Iron Deficiency Anemia
Iron Requirement in Chronic Kidney Disease
Classification of Iron Deficiency in CKD
Treating Iron Deficiency in CKD Patients
Side Effects of Iron Supplementation in CKD
Methods of Restoring Iron
Oral Iron Therapy
IV Iron-Infusion Therapy
Intravenous (IV) Iron
Conditions for Receiving Iron Injections
Injection Procedure
Categories of Iron Injections
Suitability of IV Iron Preparation
Suitability of Regimen
Management of Iron Doses
Effectiveness of Iron Injection
Requirement of Test Dose
Adverse Effects of Iron Injections
Iron Therapy: Caution
Duration of Iron Infusion
Iron Overdose
Iron-Out-of-Balance Therapies
Blood Donation
Therapeutic Phlebotomy
Red Cell Apheresis
Iron Chelation Therapy
Iron-Chelating Drugs
Desferrioxamine or Desferal
Deferiprone or Ferriprox
Conditions for Undergoing Iron Chelation Therapy
Kinds of Chelation Therapy
Side Effects Caused by IV Iron Chelation

5. PRODUCT LAUNCHES/APPROVALS

FDA approves Injectafer® for the Treatment of IDA
Takeda Pharmaceutical Company Introduces Rienso® in Europe
Pharmacosmos Launches Monofer® Intravenous Iron Drug

6. RECENT INDUSTRY ACTIVITY

American Regent Steps Up Injectafer® Promotions
AMAG Files for Rienso Label Expansion in Europe
AMAG Receives FDA Complete Response Letter for Feraheme®
Vifor Pharma and Zeria Pharmaceutical Co., Ltd. Sign Exclusive Licensing Agreement for Ferinject® in Japan
Watson Pharmaceuticals Changes Name to Actavis
Luitpold Pharmaceuticals Obtains FDA Acceptance for Review of Injectafer® NDA
AMAG Pharmaceuticals Receives FDA Acceptance for Feraheme® sNDA Review
Takeda Issues Rienso Recall in Switzerland
EC Approves Takeda's Rienso® to Treat Anemia
BioLink Life Sciences to Commence Phase I Trial of FCP